Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study

View Full Paper
Ask AI
Bookmark
Share

Authors

BHBenjamin Heyman

Discussion

Loading...

Member takes

Overview

Phase II trial shows 76% Complete Response in previously untreated follicular lymphoma, highlighting minimal residual disease rates.

Key Points

  • The combination therapy led to a significant progression-free survival of 82%, demonstrating its impact on follicular lymphoma.
  • With 92.5% overall response rate, the triplet regimen proved effective, particularly with 76% achieving a Complete Response at 12 months.
  • A single arm Phase II trial evaluated safety and efficacy across 4 comprehensive cancer centers in patients with follicular lymphoma.
  • Treatment resulted in minimal residual disease negativity in 80% of those evaluated, suggesting promising long-term outcomes.

Cite This Study

Benjamin Heyman (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dffchttps://doi.org/10.1182/blood-2025-5378
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of zanubrutinib, rituximab, and venetoclax combination regimen in previously untreated follicular lymphoma: A Phase II trial from the bbc study2025
  2. 2Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma2025 · 1 citations
  3. 3Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).2025
  4. 4Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia2025 · 3 citations
  5. 5Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma2025 · 5 citations